Finasteride and Suicidal Ideation — What the 2023 EMA Label Update Means

In 2023, the European Medicines Agency (EMA) updated the prescribing information for finasteride 1 mg (Propecia and generics) to include suicidal ideation and suicidal behaviour as potential adverse reactions. This page explains what the label change means, what the underlying evidence shows, and how to assess your personal risk.

What the EMA Label Change Says

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed post-marketing data and pharmacovigilance reports and concluded that a causal relationship between finasteride 1 mg and suicidal ideation/behaviour could not be excluded. As a result, suicidal ideation and suicidal behaviour were added to the “Not known” frequency category in the finasteride 1 mg Summary of Product Characteristics (SmPC) — meaning frequency cannot be estimated from available data.

This update applies to the EMA-regulated EU/UK market. The US FDA has not made an equivalent label update as of mid-2026, though the FDA label does include depression as a potential adverse effect.

What the Evidence Actually Shows

The evidence base for finasteride and psychiatric effects is mixed and methodologically complex:

• Randomised controlled trials: The pivotal Phase III RCTs (Kaufman 1998) did not show a statistically significant increase in depression or suicidality vs. placebo — but these trials were not designed or powered to detect rare psychiatric events.
• Pharmacovigilance data: Post-marketing surveillance, the FDA Adverse Event Reporting System (FAERS), and the EMA’s EudraVigilance database contain case reports of suicidal ideation and completed suicide in finasteride users. These are spontaneous reports and cannot establish causation.
• Observational studies: Dillon et al. (2020, JAMA Dermatology) found a statistically significant association between finasteride use and depression (hazard ratio ~1.94 in the 18–45 age group). However, observational confounding is substantial — men seeking hair loss treatment may have pre-existing psychological distress.
• Neurosteroid mechanism: Finasteride inhibits 5-alpha-reductase, which also converts progesterone to allopregnanolone — a positive GABA-A receptor modulator with known anxiolytic and mood-stabilising effects. Reduced allopregnanolone has been proposed as a neurobiological mechanism linking finasteride to mood effects (Melcangi et al.; Irwig 2012). This is biologically plausible but not definitively proven in humans.
• Post-Finasteride Syndrome (PFS): A subset of men report persistent neuropsychiatric symptoms after stopping finasteride, including depression, anhedonia, and suicidal ideation. The PFS Foundation registry includes cases of suicide. The causal chain from finasteride → neurosteroid disruption → psychiatric harm remains under active investigation.

Absolute Risk Context

Suicidal ideation is listed at “Not known” frequency in the SmPC — meaning it is a rare or very rare event, or the frequency cannot be reliably quantified from available data. The estimated background prevalence of suicidal ideation in the general male population (the primary finasteride demographic) is approximately 1–3% per year. Whether finasteride meaningfully elevates this above background is not established with precision.

For context, the vast majority of the estimated 2–3 million finasteride users in the US do not experience psychiatric adverse effects. The label addition reflects regulatory caution and the precautionary principle — it does not mean the absolute risk is high.

Who May Be at Higher Risk

Current evidence and pharmacovigilance patterns suggest the following groups may warrant closer monitoring:

• Men aged 18–45 (the hair loss treatment demographic) with a personal or family history of depression or anxiety
• Men who have previously experienced mood changes on finasteride or other 5-alpha-reductase inhibitors (dutasteride)
• Men who have experienced sexual side effects on finasteride — sexual dysfunction is itself associated with elevated depression and suicidal ideation risk, independent of the drug
• Men with body dysmorphic disorder related to hair loss (a recognised psychiatric comorbidity)

What Prescribers Should Do

Updated guidelines based on the EMA label change recommend that prescribers:

• Take a baseline psychiatric history before initiating finasteride 1 mg
• Advise patients to report any new or worsening depression, anxiety, or changes in mood or libido
• Counsel patients that psychiatric symptoms should prompt prompt contact with a healthcare provider — not just cessation of the drug
• Document the informed consent discussion about psychiatric risks, particularly in younger men with relevant history

What to Do If You Are Experiencing Symptoms

If you are taking finasteride and notice new or worsening depression, anxiety, loss of motivation, or any thoughts of self-harm:

1. Contact your prescriber immediately. Do not simply stop the drug without guidance — abrupt discontinuation may not resolve symptoms, and stopping 5 mg finasteride (BPH) without a plan can cause urinary complications.
2. Seek emergency help if thoughts of suicide are present. Call 988 (US), 116 123 (Samaritans, UK), or go to an emergency department.
3. Document your symptoms. Time of onset relative to starting finasteride, whether symptoms are new vs. prior history, and any concurrent medications are all relevant clinical information.
4. Report to the FDA or MHRA. In the US, adverse events can be reported to FDA MedWatch. In the UK, use the MHRA Yellow Card scheme. These reports directly contribute to pharmacovigilance evidence.

Related Pages

• Finasteride and Depression — Evidence Review
• Post-Finasteride Syndrome (PFS)
• Finasteride Sexual Side Effects
• PFS Evidence Review
• Finasteride and Depression: Study-Level Evidence

---

This page is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. See our full medical disclaimer.